2026 AABB Annual Meeting Planners – Financial Relationship Disclosures

In keeping with Accreditation Council for Continuing Medical Education (ACCME) and Joint Accreditation standards for commercial support, AABB asks everyone who is in position to control the content of a continuing medical education activity to disclose all relevant financial relationships with ineligible companies. ACCME defines an ineligible company as any entity producing, marketing, re-selling or distributing health care goods used on or by patients. (Providers of clinical services directly to patients are not ineligible companies). A relevant financial relationship is in any amount occurring within the previous 24 months. Relevant financial relationships reported by faculty will be disclosed at the beginning of all continuing education sessions. Below are the relevant financial relationships reported by the AABB 2025 Annual Meeting Planners (including members of the Annual Meeting Education Committee, the AABB/THOR Joint Program planning committee, the Cord Blood Connect planning committee, and AABB staff members involved in educational planning).

These planners report having no financial relationship with ineligible companies during the past 24 months.

Aikaj Jindal
Antonio Insigne
Brian Brzezinski
Chance John Luckey
Christie Malone
Christine Jones
David Gibb
Dawn Thut
Demet Hazal Gomak
Erin Goodhue
Ethan Mack
Frances Compton
Gopal Patidar
Harry McDonald Jr.
Hyojeong Han
Jennifer Carver
Jennifer O'Brien
Jessica Poissan
Josie Pippert
Kristen Krum
Leana Serrano-Rahman
Mandy O'Leary
Melissa George
Mingmar Sherpa
Mohamed Abdelmonem
Nathan McLamb
Ping Jin
Qichao Ji
Rabia Majeed
Rachel Louise Beddard
Rada Grubovic Rastvorceva
Richard Mathews
Roxanne Clark
Rugved Pattarkine
Ruth Ross
Samantha Phou
Sehyo Yune
Selina Taylor
Sherry Hogan
Steve Armstrong (AMEC Chair)
Tumari Tutt
Veronica Gross
Victoria Costa
Vijay Bhoj
Wendell Jones
Christie Allen (AABB Staff)
Jackie Thomas (AABB Staff)

These planners report having financial relationship(s) with ineligible companies during the past 24 months.

Colleen Delaney	Advisory/Consultant: Celaid, Deverra Therapeutics; Stock Shareholder: Deverra Therapeutics
Jenna Khan	Honoraria: Hemosonics
Joanne Kurtzberg	Adv/Consult: Mesoblast, Hemex Bio, CryoCell Interational; Stock Shareholder: Celularity
Phil Spinella	Advisory/Consultant: Cerus; Stock Shareholder: Kalocyte
Melissa Stewart	Stock Shareholder: Novartis
Moritz Stolla	Grant/Research Support: Cerus Corp./Terumo BCT
Hamilton Tsang	Stock Shareholder: Pfizer, Roche, Johnson and Johnson, CRISPR Therapeutics, VIATRIS, NVIDIA, Microsoft, Amazon